Published in:
Open Access
01-12-2019 | Stroke | Review
NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes
Authors:
Pu Hong, Ruo-Nan Gu, Feng-Xian Li, Xiao-Xing Xiong, Wen-Bin Liang, Zhi-Jian You, Hong-Fei Zhang
Published in:
Journal of Neuroinflammation
|
Issue 1/2019
Login to get access
Abstract
The NLRP3 (nucleotide-binding oligomerization domain-like receptor [NLR] family pyrin domain-containing 3) inflammasome is a member of the NLR family of innate immune cell sensors. These are crucial regulators of cytokine secretions, which promote ischemic cell death and insulin resistance. This review summarizes recent progress regarding the NLRP3 inflammasome as a potential treatment for ischemic stroke in patients with diabetes, two complicated diseases that often occur together. Stroke worsens glucose metabolism abnormalities, and the outcomes after stroke are more serious for diabetic patients compared with those without diabetes. Inflammation contributes to organ injury after ischemic stroke and diabetes. Recent research has focused on inhibiting the activation of inflammasomes and thus reducing the maturation of proinflammatory cytokines such as interleukin (IL)-1β and IL-18. Studies suggest that inhibition of NLRP3 prevents or alleviates both ischemic stroke and diabetes. Targeting against the assembly and activity of the NLRP3 inflammasome is a potential and novel therapy for inflammasome-associated diseases, including ischemic stroke concomitant with diabetes.